Therapeutic Asset Ratings

105 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
HAFNIUM OXIDE Metastasis From Malignant Tumor of Cervix	Nanobiotix	P1	CC (43)
HAFNIUM OXIDE Metastasis From Malignant Tumor of Liver	Nanobiotix	P1	CC (43)
HAFNIUM OXIDE Microsatellite Instability-High Solid Malignant Tumour	Nanobiotix	P1	CC (43)
HAFNIUM OXIDE Stage IA1 Lung Cancer AJCC v8	M.D. Anderson Cancer Center	P1	CC (43)
HAFNIUM OXIDE Stage III Pancreatic Cancer AJCC v8	M.D. Anderson Cancer Center	P1	CC (43)
HAFNIUM OXIDE Stage I Lung Cancer AJCC v8	M.D. Anderson Cancer Center	P1	CC (43)
Ferumoxytol Multiple Sclerosis, Secondary Progressive	University of Utah	Early P1	CC (43)
Ferumoxytol Secondary Progressive Multiple Sclerosis	University of Utah	Early P1	CC (43)
HAFNIUM OXIDE Metastatic Malignant Solid Neoplasm	M.D. Anderson Cancer Center	P1/2	CC (43)
Pasifolate Exatecan Ovarian Neoplasms	Elucida Oncology	P1/2	CC (43)
HAFNIUM OXIDE Metastatic Renal Cell Carcinoma	Nanobiotix	P1	CC (41)
HAFNIUM OXIDE Metastatic Triple-Negative Breast Carcinoma	Nanobiotix	P1	CC (41)
HAFNIUM OXIDE Squamous Cell Carcinoma of Head and Neck	Nanobiotix	P1	CC (41)
Pasifolate Exatecan AML, Childhood	Elucida Oncology	P1	CC (41)
Pasifolate Exatecan Endometrial Cancer	Elucida Oncology	P1/2	CC (41)
Pasifolate Exatecan Fallopian Tube Cancer	Elucida Oncology	P1/2	CC (41)
Pasifolate Exatecan Ovarian Cancer	Elucida Oncology	P1/2	CC (40)
HAFNIUM OXIDE Immunotherapy	Nanobiotix	P1	C (39)
HAFNIUM OXIDE Radiotherapy	Nanobiotix	P1	C (39)
Ulintoclax Pegondrimer Non-Hodgkin Lymphoma	AstraZeneca	P1	C (39)
Ferumoxytol DLBCL - Diffuse Large B Cell Lymphoma	Medical University of Vienna	Early P1	C (38)
(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW) Esophageal Cancer	Lumicell, Inc.	P1/2	C (37)
(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW) Gastric Cancer	Lumicell, Inc.	P1/2	C (37)
Pasifolate Exatecan Acute Myeloid Leukemia	Elucida Oncology	P1	C (36)
(3RS)-1-(6-(.ALPHA.-METHYLPOLY(OXYETHYLENE)AMINO)-6-OXOHEXYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINAMIDE, (20000 MW) Colorectal Cancer	Lumicell, Inc.	P1/2	C (36)

Showing 51 to 75 of 105 assets

PreviousPage 3 of 5Next